Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GIGHAART ANRS 097)

Journal of Medical Virology

Volumn 77, Issue 3, 2005, Pages 345-350

  Delaugerre, Constance ^a,e   Peytavin, Gilles ^b   Dominguez, Stephanie ^a,c   Marcelin, Anne Genevieve ^a   Duvivier, Claudine ^a,c   Gourlain, Karine ^a   Amellal, Bahia ^a   Legrand, Mayeule ^a   Raffi, François ^d   Costagliola, Dominique ^c   Katlama, Christine ^a,c   Calvez, Vincent ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

^c INSERM   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e University Hospital of Nantes ^*  (France)

Author keywords

Combined PI; Concentration drug; HIV 1; Inhibitory quotient; Quasispecies; Resistance

Indexed keywords

AMPRENAVIR; CD4 ANTIGEN; HYDROXYUREA; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREDICTION AND FORECASTING; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; TREATMENT OUTCOME; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SALVAGE THERAPY; TREATMENT OUTCOME; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 25844439955     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20462     Document Type: Article

References (27)

1. Casado JL, Moreno S, Hertogs K, Dronda F, Antela A, Dehertogh P, Perez-Elias MJ, Moreno A. 2002. Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen. AIDS 16:47-52.
2. Corbett AH, Eron JJ, Fiscus SA, Rezk NL, Kashuba AD. 2004. The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr 36:921-928.
3. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344:472-480.
4. Deeks SG, Grant RM, Wrin T, Paxinos EE, Liegler T, Hoh R, Martin JN, Petropoulos CJ. 2003. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 17:361-370.
5. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 5:41-48.
6. Delaugerre C, Valantin MA, Mouroux M, Bonmarchand M, Carcelain G, Duvivier C, Tubiana R, Simon A, Bricaire F, Agut H, Autran B, Katlama C, Calvez V. 2001. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS 15:2189-2191.
7. Delaugerre C, Teglas JP, Treluyer JM, Vaz P, Jullien V, Veber F, Rouzioux C, Chaix ML, Blanche S. 2004. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir. J Acquir Immune Defic Syndr 37:1269-1275.
8. Devereux HL, Youle M, Johnson MA, Loveday C. 1999. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 13:F123-F127.
9. Elston R, White S, Yates P, Xu F, Richards N, Sharp S, Wire MB, Tisdale M. 2004. A genotypic inhibitory quotient (GIQ) for fosamprenavir/rtv (908/r). In XIII International HIV Drug Resistance Workshop. Edited by A. Therapy. Tenerife, Spain.
10. Gonzalez de Requena D, Garcia-Benayas T, Gallego O, Blanco F, Valer L, Jimenez-Nacher I, Rendon AL, Soriano V. 2004. Predictive power of genotypic inhibitory quotient and lopinavir plasma levels in both efficacy and lipid elevations of LPV/r-based salvage regimens at 48 weeks. In 11th Conference on Retroviruses and opportunistic infections. San Francisco, USA.
11. Hance AJ, Lemiale V, Izopet J, Lecossier D, Joly V, Massip P, Mammano F, Descamps D, Brun-Vezinet F, Clavel F. 2001. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 75:6410-6417.
12. Izopet J, Souyris C, Sandres-Saune K, Puissant B, Obadia M, Pasquier C, Puel J, Blancher A, Massip P. 2002. Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype. J Med Virol 68:305-310.
13. Katlama C, Dominguez S, Gourlain K, Duvivier C, Delaugerre C, Legrand M, Tubiana R, Reynes J, Molina JM, Peytavin G, Calvez V, Costagliola D, GIGHAART study group. 2004. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: A randomized controlled trial (ANRS 097). AIDS 18:217-226.
14. Kijak GH, Simon V, Balfe P, Vanderhoeven J, Pampuro SE, Zala C, Ochoa C, Cahn P, Markowitz M, Salomon H. 2002. Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure. J Virol 76:7000-7009.
15. Lawrence J, Mayers DL. Hullsiek KH, Collins G, Abrams DI, Reisler RB, Crane LR, Schmetter BS, Dionne TJ, Saldanha JM, Jones MC, Baxter JD. 2003. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 349:837-846.
16. Marcelin AG, Cohen-Codar I, King M, Guillevic E, Lamotte C, Chauvin JP, Kempf DJ, Peytavin G, Calvez V. 2003a. Virological and pharmacological parameters predicting the response to LPV/r. In 2nd IAS Conference on HIV Pathogenesis and Treatment, pp. S416. Paris, France: Antiviral Therapy.
17. Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait Mohand H, Cacace R, Bonmarchand M, Wirden M, Simon A, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V. 2003b. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 47: 594-600.
18. Miller V, Cozzi-Lepri A, Hertogs K, Gute P, Larder B, Bloor S, Klauke S, Rabenau H, Phillips A, Staszewski S. 2000a. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antivir Ther 5:49-55.
19. Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, Larder B, Lutz T, Gute P, Weidmann E, Rabenau H, Phillips A, Staszewski S. 2000b. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14:2857-2867.
20. Molla A, Mo H, Vasavanonda S, Han L, Lin CT, Hsu A, Kempf DJ. 2002. In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob Agents Chemother 46:2249-2253.
21. Montaner JS, Harrigan PR, Jahnke N, Raboud J, Castillo E, Hogg RS, Yip B, Harris M, Montessori V, O'Shaughnessy MV. 2001. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 15:61-69.
22. Mouroux M, Yvon-Groussin A, Peytavin G, Delaugerre C, Legrand M, Bossi P, Do B, Trylesinski A, Diquet B, Dohin E, Delfraissy JF, Katlama C, Calvez V. 2000. Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance. J Clin Microbiol 38: 2726-2730.
23. Peytavin G, Legrand M, Duvivier C, Lamotte C, Dominguez S, Delaugerre C, Costagliola D, Calvez V, Katlama C. 2002. Relationship between trough plasma concentrations of HIV antiretroviral drugs and virological response and mutations reversion in GIGHAART trial (ANRS 097). In Program and abstracts of the XIV International AIDS Conference. Barcelona, Spain.
24. Piketty C, Race E, Castiel P, Belec L, Peytavin G, Si-Mohamed A, Gonzalez-Canali G, Weiss L, Clavel F, Kazatchkine MD. 2000. Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz. AIDS 14:626-628.
25. Raguin G, Chene G, Morand-Joubert L, Taburet AM, Droz C, Le Tiec C, Clavel F, Girard PM. 2004. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Antivir Ther 9:615-625.
26. Ruiz L, Ribera E, Bonjoch A, Romeu J, Martinez-Picado J, Paredes R, Diaz M, Marfil S, Negredo E, Garcia-Prado J, Tural C, Sirera G, Clotet B. 2003. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: The Retrogene Study. J Infect Dis 188:977-985.
27. Stephan C, Hentig N, Kourbeti I, Dauer B, Mosch M, Lutz T, Klauke S, Harder S, Kurowski M, Staszewski S. 2004. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 18:503-508.